Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy

Blood

Volumn 92, Issue 4, 1998, Pages 1172-1183

  Ding, Wei ^b   Li, Yun Ping ^b   Mobile, Lucio M ^b   Grills, George ^b   Carrera, Ines ^b   Paietta, Elisabeth ^b   Tallman, Martin S ^b   Wiernik, Peter H ^b   Gallagher, Robert E ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CYTARABINE; DAUNORUBICIN; DNA; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE FUSION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MISSENSE MUTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032529284     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.4.1172     Document Type: Article

References (63)

1. Breitman TR, Collins SJ, Keene BR: Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57:1000, 1981
2. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L: All-trans retinoic acid in acute promyelocytic leukemia. II. In vitro studies: Structure-function relationship. Blood 76:1710, 1990
3. Elliott S, Taylor K, White S, Rodwell R, Marlton P, Meagher D, Wiley J, Taylor D. Wright S, Timms P: Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 79:1916, 1992
4. Degos L, Dombret H, Chomienne C, Daniel M-T, Miclea J-M, Chastang C, Castaigne S, Fenaux P: All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643, 1995
5. Huang M-e, Ye Y-c, Chen S-r, Chai J-r, Lu J-X, Lin Z, Gu L-j, Wang Z-y: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
6. Chen Z-X, Xue Y-Q, Zhang R, Tao R-F, Xia X-M, Li C, Wang W, Zu W-Y, Yao X-Z, Ling B-J: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413, 1991
7. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704, 1990
8. Fenaux P, Le Deley MC, Castaigne S: Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomization trial. Blood 82:3241, 1993
9. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr: All-trans-retinoic acid for acute promyelocytic leukemia: Results of the New York study. Ann Intern Med 120:278, 1994
10. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kabayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoda A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202, 1995
11. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F: Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014, 1997
12. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JE, Ogden A, Shepherd L, Willman CL, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
13. Fenaux P, Chastang C, Sanz M, Archimbaud E, Dombret H, Link G, Guerci A, Gegueux N, San Miguel J, Rayon C, Zittoun R, Gardin C, Maoisel F, Fey M, Travade P, Reiffers J, Stamatoulas A, Stoppa AM, Guy H, Buzyn A, Hayat M, Castaigne S, Chomienne C, Degos L: Effect of ATRA in newly diagnosed acute promyelocytic leukemia (APL): Results of 2 European multicenter trials (APL 91 and APL 93 trials). Anticancer Res 17:3937, 1997
14. Warrell R Jr: Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications. Blood 82:1949, 1993
15. Muindi J, Frankel S, Huselton C, DeGrazia F, Garland W, Young C, Warrell RP Jr: Clinical pharmacology of oral all-trans retinoic acid with acute promyelocytic leukemia. Cancer Res 52:2138, 1992
16. Muindi J, Frankel S, Miller WH Jr, Jakubowski A, Scheinberg D, Young C, Dmitrovsky E, Warrell RP Jr: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299, 1992
17. Adamson P, Boylan J, Balis F, Murphy R, Godwin K, Gudas L, Poplack D: Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 53:472, 1993
18. Muindi J, Young C: Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 53:1226, 1993
19. Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C: Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 52:3329, 1992
20. Delva L, Cornic M, Balitrand N, Guidez F, Miclea J-M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C: Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82:2175, 1993
21. Miller W Jr, Jakubowski A, Tong W, Miller V, Rigas J, Benedetti F, Gill G, Truglia J, Ulm E, Shirley M, Warrell R Jr: 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85:3021, 1995
22. Hallam SJ, Rao S, Wiernik PH, Gallagher RE: Cytoplasmic retinoic acid binding protein-II mRNA measurements in acute promyelocytic leukemia. Proc Am Assoc Cancer Res 36:215, 1995
23. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Lo Coco F, Avvisati G, Gambacorti-Passerini C, Adamo S, Levin AA, Pelicci PG, Nervi C: Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARα-mediated increase of type II transglutaminase. Blood 87:1939, 1996
24. Rosenauer A, Railson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH Jr: Alteration in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 88:2671, 1996
25. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr: A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 89:4282, 1997
26. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124, 1998
27. Benedetti L, Levin AA, Scicchitano BM, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, Pelicci PG, Nervi C: Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 90:1175, 1997
28. Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T: Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: Differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia. Leukemia 11:1950, 1997
29. Robertson K, Emami B, Collins S: Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 80:1885, 1992
30. Li Y-P, Said F, Gallagher R: Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-α. Blood 83:3298, 1994
31. Dore BT, Momparler RL: Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. Leuk Res 20:761, 1996
32. Morosetti R, Grignani F, Liberatore C, Pelicci PG, Schiller GJ, Kizaki M, Bartram CR, Miller CW, Koeffler HP: Infrequent alterations of the RARα gene in acute myelogenous leukemias. retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines. Blood 87:4399, 1996
33. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub M-P, Durand B, Lanotte M, Berger R, Chambon P: Structure, localization and transcriptional properties of two classes of retinoic acid receptor a fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins. EMBO J 11:629, 1992
34. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de The H: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13:1073, 1994
35. Dyck JA, Maul GG, Miller WH Jr, Chen JC, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333, 1994
36. Weis K, Rambaud S, Laqvau C, Jansen J, Carvalgo T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia. Cell 76:345, 1994
37. Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmerti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti L, Peschele C, Pelicci PG: Effects on differentiation by the promyelocytic leukemia PML/RARα protein depend on the fusion of the PML protein dimerization and RARα DNA binding domains. EMBO J 15:4949, 1996
38. Altabef M, Garcia M, Lavau C, Bae S-C, Dejean A, Samarut J: A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARα fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. EMBO J 15:2707, 1996
39. Gallagher RE, Li Y-P, Rao S, Paietta E, Andersen J, Etkind P, Tollman MS, Wiernik PH: Characterization of acute promyelocytic leukemia cases with PML-RARα break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 86:1540, 1995
40. Sarkar G, Kapelner S, Sommer S: Formamide can dramatically improve the specificity of PCR. Nucleic Acid Res 18:7465, 1990
41. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 44:169, 1980
42. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH: Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 90:1656, 1997
43. Li YP, Andersen J, Zelent A, Rao S, Paietta E, Tallman MS, Wiernik PH, Gallagher RE: RARα 1/RARα 2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study. Blood 90:306, 1997
44. Fagioli M, Alcalay M, Pandolfi P, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, Pelicci P: Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 7:1083, 1992
45. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66:663, 1991
46. Borden KLB, Boddy MN, Lally J, O'Reilly NJ, Martin S, Howe K, Solomon E, Freemont PS: The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J 14:1532, 1995
47. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
48. Giguere V, Ong ES, Segui P, Evans RM: Identification of a receptor for the morphogen retinoic acid. Nature 330:624, 1987
49. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10:940, 1996
50. Warrell R Jr, Frankel S, Miller WH Jr, Steinberg D, Itri L, Hittleman W, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon M, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324:1385, 1991
51. Smith MA, McCaffrey RP, Karp JE: The secondary leukemias: Challenges and research directions. J Natl Cancer Inst 88:407, 1996
52. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354, 1997
53. Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik P: The immunophenotype of acute promyelocytic leukemia (APL): An ECOG study. Leukemia 8:1108, 1994
54. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcriptase polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82:1689, 1993
55. Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D: Crystal structure of the RAR-γ ligand binding domain bound to all-trans retinoic acid. Nature 378:681, 1995
56. Tate BF, Grippo JF: Mutagenesis of the ligand binding domain of the human retinoic acid receptor a identifies critical residues for 9-cis retinoic acid binding. J Biol Chem 270:20258, 1995
57. Le Douarin B, Nielsen AL, Garnier J-M, Ichinose H, Heanmougin F, Losson R, Chambon P: A possible involvement of TIF1α and TIF1β in the epigenetic control of transcription by nuclear receptors. EMBO J 15:6701, 1996
58. Heery DM, Kalkhoven E, Hoare S, Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733, 1997
59. vom Baur E, Zechel C, Heery D, Heine MJS, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P, Losson R: Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG and TIF1. EMBO J 15:110, 1996
60. Schultz RM, Liebman MN: Protein I: Composition and structure, in Devlin TM (ed): Textbook of Biochemistry (ed 3). New York, NY, Wiley-Liss, 1992, p 30
61. de The H, Marchio A, Tiollais P, Dejean A: A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellualr carcinoma. Nature 330:667, 1987
62. Okai Y, Higashi-Okai K, Nakamura S-i, Yano Y, Otani S: Suppressive effects of retinoids, carotenoids and antioxidant vitamins on heterocyclic amine-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002). Mutat Res 368:133, 1996
63. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum F: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995